Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Simplicity Analysis Software

By Drug Discovery Trends Editor | December 3, 2008

Guava Technologies' Guava Simplicity Analysis SoftwareGuava Technologies, Inc. released information on their recent advancements that describe an experimental methodology and the new Guava Simplicity Analysis Software which exploit the advantages of plate-based flow technology. These technological improvements result in an overall process that can expedite the drug discovery process by providing a means for extraction of key findings from the complex data sets encountered with functional screening of siRNA knockdown assays.

The Guava EasyCyte Plus System, with integrated Guava Simplicity Software, provides a platform for secondary target validation and compound screening. Guava Technologies’ flow cytometers overcome the limitations of inference-based measurements of transfection efficiency and protein knockdown through direct quantitative analysis of populations at the single cell level, according to the company. The Simplicity Analysis Software’s intuitive architecture and ease of use facilitates the process of asking biological questions on multi-dimensional data sets through visualization of user-defined parameters in the form of heat-maps. Comparative results are displayed at the experiment level rather than on an individual well/sample basis.

www.guavatechnologies.com

Published in Drug Discovery & Development magazine: Vol. 11, No. 12, December, 2008, p.7.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50